AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25256893 — intervention group
Group type: EXPERIMENTAL
Intervention: ICGR15
Number of subjects: 878
Study 23270328 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0
Study 23270328 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19725815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium ophthalmic solution (BF)
Number of subjects: 62
Study 19725815 — intervention group
Group type: COMPARATOR
Intervention: Steroidal solution (ST)
Number of subjects: 62
Study 17428949 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent HPV16 vaccine
Number of subjects: 0
Study 17428949 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine
Number of subjects: 0
Study 15797982 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine HCl ophthalmic solution 0.5%
Number of subjects: 22
Study 15797982 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (saline) eye drops
Number of subjects: 22
Study 11970775 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs and evaluations framed positively or negatively
Number of subjects: 0
Study 11970775 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplicative model
Number of subjects: 0
Study 9583551 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate, 0.3 mg/kg, and fentanyl, 1 microg/kg
Number of subjects: 30
Study 9583551 — intervention group
Group type: COMPARATOR
Intervention: Ketamine, 1 mg/kg, and fentanyl, 1 microg/kg
Number of subjects: 30
Study 8580227 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-988 capsules/CCK-4
Number of subjects: 30
Study 8580227 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules/CCK-4
Number of subjects: 30
Study 8580227 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules/placebo
Number of subjects: 30
Study 2679240 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine, 3 g IV as a bolus, followed by continuous intravenous infusion of 2 mg/kg/min for thirty minutes
Number of subjects: 18
Study 2679240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1208760 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 36
Study 1208760 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (8 mug/kg)
Number of subjects: 36
Study 30977897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training
Number of subjects: 39
Study 30977897 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 39
Study 30977897 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 39
Study 27865117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump therapy
Number of subjects: 600
Study 27865117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraaortic balloon pump therapy)
Number of subjects: 600
Study 27865117 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CI levels
Number of subjects: 600
Study 27865117 — intervention group
Group type: EXPERIMENTAL
Intervention: High CI levels at day 3
Number of subjects: 600
Study 25859764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT-SAD) for 6 weeks, 12 sessions in a group format, 90 minutes each, administered by Ph.D. psychologists
Number of subjects: 177
Study 25859764 — intervention group
Group type: COMPARATOR
Intervention: Light Therapy for 6 weeks, 10,000-lux cool-white fluorescent light, initiated at 30 minutes each morning
Number of subjects: 177
Study 24383855 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM subjects
Number of subjects: 164
Study 24383855 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD subjects
Number of subjects: 164
Study 24383855 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM-CAD subjects
Number of subjects: 164
Study 24383855 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12
Number of subjects: 164
Study 24383855 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ
Number of subjects: 164
Study 24383855 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4
Number of subjects: 164
Study 24383855 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5
Number of subjects: 164
Study 24383855 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-13
Number of subjects: 164
Study 23041804 — intervention group
Group type: EXPERIMENTAL
Intervention: CEC curtains
Number of subjects: 30
Study 23041804 — intervention group
Group type: COMPARATOR
Intervention: Standard curtains
Number of subjects: 30
Study 18947437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (0-2 g/d) for up to 10 weeks
Number of subjects: 0
Study 17725415 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) once daily (QD)
Number of subjects: 546
Study 17725415 — intervention group
Group type: COMPARATOR
Intervention: Stavudine (d4T) twice daily
Number of subjects: 546
Study 17725415 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of K103N mutation
Number of subjects: 546
Study 15686273 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine hospital procedure of compressed air exposure to 240 kPa for approximately 115 min with 12 min of terminal oxygen breathing.
Number of subjects: 9
Study 15686273 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised profile with 12 and 24 min of terminal oxygen breathing and a Nitrox profile (40.5% O2 in Nitrogen during 90 min of isobaric phase).
Number of subjects: 9
Study 11728950 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (0.8 mg/kg/d) for 1 month
Number of subjects: 0
Study 11728950 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 11728950 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9226337 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 20
Study 9226337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8435260 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1 and alfentanil 10 micrograms kg‐1
Number of subjects: 60
Study 8435260 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1, alfentanil 10 micrograms kg‐1, and lignocaine 1 mg kg‐1
Number of subjects: 60
Study 8435260 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Number of subjects: 60
Study 8435260 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1, alfentanil 20 micrograms kg‐1, and lignocaine 1 mg kg‐1
Number of subjects: 60
Study 8435260 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine group (with lignocaine)
Number of subjects: 60
Study 3679064 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12
Study 3679064 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 12
Study 3679064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29160731 — intervention group
Group type: EXPERIMENTAL
Intervention: cART with EPOCH
Number of subjects: 0
Study 29160731 — intervention group
Group type: COMPARATOR
Intervention: non-cART
Number of subjects: 0
Study 28393774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rajyoga meditation
Number of subjects: 150
Study 28393774 — intervention group
Group type: COMPARATOR
Intervention: Control group (patient counseling)
Number of subjects: 150
Study 26247196 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 0
Study 26247196 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 24011104 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence (EI) training group
Number of subjects: 590
Study 24011104 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 590
Study 21182491 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (20 µg·h(‐1), 144 h)
Number of subjects: 22
Study 21182491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (25 µg·h(‐1), 72 h)
Number of subjects: 22
Study 21182491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21182491 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine and Fentanyl
Number of subjects: 22
Study 18311330 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme iron supplemented filling in low iron feed
Number of subjects: 2
Study 18311330 — intervention group
Group type: COMPARATOR
Intervention: Normal feed with ferrous sulphate
Number of subjects: 2
Study 17165496 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-changeable electroacupuncture at Qimen (LR 14), Liangmen (ST 21), Riyue (GB 24), Danshu (BL 19), Ganshu (BL 18), Yanglingquan (GB 34), and Dannang (EX-LE6)
Number of subjects: 120
Study 17165496 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine Paishi Decoction, 40 mL of 33% magnesium sulfate, 30 mL of 0.5% hydrochloric acid, fat diet, and Tuian Yunjing Instrument
Number of subjects: 120
Study 14556128 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.5%
Number of subjects: 62
Study 14556128 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.5%
Number of subjects: 62
Study 10765962 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPS (2 mg/kg body weight) injected intravenously
Number of subjects: 80
Study 9050975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil/trandolapril
Number of subjects: 205
Study 9050975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol/chlorthalidone
Number of subjects: 205
Study 9050975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril/hydrochlorothiazide
Number of subjects: 205
Study 9050975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 8288503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 1 g tds
Number of subjects: 50
Study 8288503 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g tds
Number of subjects: 50
Study 3506198 — intervention group
Group type: EXPERIMENTAL
Intervention: Village health workers (VHWs) trained mothers in experimental villages
Number of subjects: 647
Study 3506198 — intervention group
Group type: COMPARATOR
Intervention: Control villages (no training)
Number of subjects: 647
Study 3506198 — intervention group
Group type: EXPERIMENTAL
Intervention: Solutions made in experimental villages
Number of subjects: 647
Study 3506198 — intervention group
Group type: COMPARATOR
Intervention: Solutions made in control villages
Number of subjects: 647
Study 29050992 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 84496
Study 29050992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84496
Study 27315583 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg)
Number of subjects: 116
Study 27315583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (500 mg)
Number of subjects: 116
Study 25902591 — intervention group
Group type: EXPERIMENTAL
Intervention: Heifer community development activities
Number of subjects: 607
Study 25902591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Heifer activities for the first year)
Number of subjects: 607
Study 22840293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenterics intragastric balloon (BIB)
Number of subjects: 18
Study 22840293 — intervention group
Group type: COMPARATOR
Intervention: Sham BIB placement
Number of subjects: 18
Study 20155359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 49
Study 20155359 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 49
Study 20155359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS) for crossover patients
Number of subjects: 49
Study 20155359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS) for bleeding intensity 1 and 2 patients
Number of subjects: 49
Study 18187087 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise (Trained; n = 10)
Number of subjects: 20
Study 18187087 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (Control; n = 10)
Number of subjects: 20
Study 15678632 — intervention group
Group type: EXPERIMENTAL
Intervention: Public perception of alcohol use by physicians on duty
Number of subjects: 408
Study 15678632 — intervention group
Group type: EXPERIMENTAL
Intervention: Public beliefs about alcohol use by physicians on duty
Number of subjects: 408
Study 11691702 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection strategies (1997-1998)
Number of subjects: 0
Study 11691702 — intervention group
Group type: COMPARATOR
Intervention: Usual detection methods (1993-1994)
Number of subjects: 0
Study 9586668 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (1600 mg/day orally)
Number of subjects: 300
Study 9586668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 8031562 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 30
Study 8031562 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 30
Study 2686433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diphenylhydantoin (1,000 mg)
Number of subjects: 90
Study 2686433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 4926948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 274
Study 4926948 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan
Number of subjects: 274
Study 4926948 — intervention group
Group type: COMPARATOR
Intervention: Control (Blood Urea Concentration < 40 mg/100 ml)
Number of subjects: 274
Study 4926948 — intervention group
Group type: COMPARATOR
Intervention: Control (Blood Urea Concentration 40-79 mg/100 ml)
Number of subjects: 274
Study 4926948 — intervention group
Group type: COMPARATOR
Intervention: Control (Blood Urea Concentration ≥ 80 mg/100 ml)
Number of subjects: 274
Study 7352850 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride (60 mg daily)
Number of subjects: 68
Study 7352850 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride (increased doses)
Number of subjects: 68
Study 7352850 — intervention group
Group type: COMPARATOR
Intervention: Methadyl acetate
Number of subjects: 68
Study 30194663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose daily prednisolone (0.2-0.3 mg/kg daily)
Number of subjects: 61
Study 30194663 — intervention group
Group type: COMPARATOR
Intervention: Standard alternate-day prednisolone (0.5-0.7 mg/kg alternate day)
Number of subjects: 61
Study 28444800 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic meatus scoring scale (meatuscopy)
Number of subjects: 310
Study 28444800 — intervention group
Group type: COMPARATOR
Intervention: Sniff test
Number of subjects: 310
Study 25400127 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme with telephone follow-up (N = 30)
Number of subjects: 60
Study 25400127 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 30)
Number of subjects: 60
Study 25400127 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Educational programme and Control)
Number of subjects: 60
Study 24163121 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 200
Study 24163121 — intervention group
Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 200
Study 21777100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (n=15, dentin group)
Number of subjects: 65
Study 21777100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E3 (n=15, with cuspal coverage and cervical enamel)
Number of subjects: 65
Study 21777100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E1 and E2 (n=15 each, with cervical enamel)
Number of subjects: 65
Study 21777100 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=5, intact teeth without preparation or restoration)
Number of subjects: 65
Study 21777100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D
Number of subjects: 65
Study 21777100 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups E1, E2, and E3
Number of subjects: 65
Study 19162226 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 19162226 — intervention group
Group type: COMPARATOR
Intervention: Amobarbital
Number of subjects: 40
Study 17322141 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 37
Study 17322141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg)
Number of subjects: 37
Study 17322141 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg) with nisoldipine (10 mg)
Number of subjects: 37
Study 15083369 — intervention group
Group type: COMPARATOR
Intervention: ACE I/D genotype
Number of subjects: 57
Study 15083369 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program
Number of subjects: 57
Study 11684988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled inverse ratio ventilation (PC-IRV) 2:1
Number of subjects: 17
Study 11684988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled inverse ratio ventilation (PC-IRV) 4:1
Number of subjects: 17
Study 11684988 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV) 1:2
Number of subjects: 17
Study 9579838 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2/IFN-alpha and tamoxifen
Number of subjects: 128
Study 9579838 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen only
Number of subjects: 128
Study 8279942 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg per hour of recombinant human IGF-I
Number of subjects: 11
Study 8279942 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study 3183852 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and dipyridamole
Number of subjects: 58
Study 3183852 — intervention group
Group type: COMPARATOR
Intervention: Supportive management only
Number of subjects: 58
Study 31619121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilingual listeners (n=29)
Number of subjects: 48
Study 31619121 — intervention group
Group type: COMPARATOR
Intervention: Monolingual listeners (n=19)
Number of subjects: 48
Study 29017282 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL6)
Number of subjects: 186
Study 29017282 — intervention group
Group type: EXPERIMENTAL
Intervention: IP10
Number of subjects: 186
Study 29017282 — intervention group
Group type: EXPERIMENTAL
Intervention: Monokine induced by IFN-γ (MIG)
Number of subjects: 186
Study 29017282 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β (IFNβ)
Number of subjects: 186
Study 29017282 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6, IL1β, IL1Rα (multivariate analysis)
Number of subjects: 186
Study 29017282 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ (multivariate analysis)
Number of subjects: 186
Study 29017282 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of TB-associated markers (IL6, IP10, sCD14, IFNγ)
Number of subjects: 186
Study 27122214 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U Botulinum‐A toxin injection
Number of subjects: 60
Study 27122214 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 U Botulin‐A toxin injection
Number of subjects: 60
Study 27122214 — intervention group
Group type: COMPARATOR
Intervention: 200 U Botulin‐A toxin injection
Number of subjects: 60
Study 27122214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of Botulinum‐A toxin
Number of subjects: 60
Study 23337181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based thin-ideal internalization reduction program
Number of subjects: 977
Study 23337181 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 977
Study 21485709 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Xobix)
Number of subjects: 18
Study 21485709 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Melfax)
Number of subjects: 18
Study 19690253 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Ranger
Number of subjects: 450
Study 19690253 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐MAC Storz Berci DCI
Number of subjects: 450
Study 19690253 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 450
Study 16983600 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐(‐)‐linalool
Number of subjects: 24
Study 16983600 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐(+)‐linalool
Number of subjects: 24
Study 16983600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both linalool enantiomers
Number of subjects: 24
Study 16983600 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 15195759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 20
Study 15195759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with minimal HE
Number of subjects: 20
Study 15195759 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 20
Study 11265020 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized protocol for ventilatory support
Number of subjects: 67
Study 11265020 — intervention group
Group type: COMPARATOR
Intervention: Nonprotocol (physician-directed ventilatory support)
Number of subjects: 67
Study 9492717 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraamniotic saline infusion
Number of subjects: 85
Study 9492717 — intervention group
Group type: COMPARATOR
Intervention: Intracervical application of dinoprost 0.5 mg (prostaglandin)
Number of subjects: 85
Study 8045656 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg before operation)
Number of subjects: 18
Study 8045656 — intervention group
Group type: COMPARATOR
Intervention: Control (no allopurinol)
Number of subjects: 18
Study 2692571 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxepa (20 capsules/day)
Number of subjects: 21
Study 2692571 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 21
Study 4908341 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (100 mg, twice daily for 10 days)
Number of subjects: 197